I get gout attacks but my heart tests are normal — do I still need monitoring?

This study found that the increased cardiovascular risk accumulates over time, with heart failure risk emerging earlier and stroke and heart attack risk becoming statistically significant after three to five years in the high-flare group. Normal results at one point in time do not rule out progressive risk accumulation. If you are experiencing more than three gout flares annually, discussing cardiovascular risk factor management with your GP — blood pressure, lipids, blood sugar, smoking status — is appropriate regardless of what your current tests show.

Why would joint inflammation affect the heart?

Gout flares involve activation of the NLRP3 inflammasome, which produces inflammatory cytokines — particularly interleukin-1β, interleukin-6, and TNF-α. When this happens repeatedly, the systemic inflammatory load damages the lining of blood vessels (endothelium) and accelerates atherosclerosis. The same inflammatory pathway is implicated in cardiovascular risk in other inflammatory conditions including rheumatoid arthritis and lupus. The heart is not directly involved in the joint — but it is affected by the systemic chemical environment that repeated flares produce.

Does this mean I need to be on urate-lowering therapy?

This study's findings add weight to the argument for adequate long-term urate control in patients with frequent gout flares — not only to prevent joint damage, but potentially to reduce systemic inflammatory load and cardiovascular risk. The decision about urate-lowering therapy is an individual one, made with your GP based on flare frequency, serum urate levels, comorbidities, and tolerability. The cardiovascular risk data provides a stronger case for not delaying that conversation if you are flaring three or more times per year.

Three or more gout flares a year raises heart risk by up to 45%, study finds

What just happened

A multinational observational study published in Rheumatology this month has given general practice a new cardiovascular risk signal hiding in plain sight: the frequency of gout flares.

The study followed 44,705 adults from their first treated gout flare in 2017, tracking cardiovascular outcomes over up to seven years. The findings establish a clear dose-response relationship between flare frequency and heart risk. Patients experiencing four to six treated flares annually faced a 24% higher risk of major adverse cardiovascular events (MACE) compared to those with three or fewer. Those with seven or more annual flares faced a 45% higher risk.

Heart failure emerged as the most sensitive marker — elevated at 17% higher risk with four to six flares per year and 27% higher with seven or more. Stroke and heart attack required greater cumulative inflammatory exposure, becoming statistically significant after three to five years in the high-flare group.

The researchers propose a practical clinical threshold: three or more gout flares per year as a trigger for intensive cardiovascular risk stratification.

The both-and

This is not a surprising mechanism — but the data confirm it

The link between gout and cardiovascular disease has been observed for decades at an epidemiological level. What this study contributes is a dose-response relationship and a mechanistic framework that makes sense of it.

Gout flares involve repeated activation of the NLRP3 inflammasome — an inflammatory pathway that produces interleukin-1β, interleukin-6, and TNF-α. In the context of a single flare, this is a localised inflammatory response. In the context of four, six, or seven flares a year, it is a systemic inflammatory exposure that the cardiovascular system bears the cumulative cost of. The endothelial damage and accelerated atherosclerosis that follow are the same processes implicated in the cardiovascular risk associated with rheumatoid arthritis and systemic lupus erythematosus.

The novelty here is not the mechanism — it is the quantification. Three flares per year as a threshold is a usable clinical number. It gives a GP looking at a gout patient a specific trigger for escalating cardiovascular risk work rather than a vague impression that “gout is bad for your heart.”

What this means for women

Gout is still perceived culturally and clinically as a condition of middle-aged men eating red meat and drinking port. That framing is outdated. Gout rates in women rise sharply after menopause, as oestrogen-mediated urate excretion is lost. Postmenopausal women on diuretics for blood pressure — a common clinical combination — have particularly elevated risk of hyperuricaemia and gout.

The result is a population that is both underflagged for gout (because the prior probability in a woman is lower in the clinician’s mind) and underrecognised for the cardiovascular implications of frequent flares when they do occur. The cardiovascular risk associated with frequent flares in women has not been studied in isolation in this dataset — the cohort is 44,705 adults without a sex-stratified breakdown in the Medical Republic reporting — but the biological mechanism applies regardless of sex.

A 45-year-old woman with frequent gout flares and a blood pressure already on the borderline for treatment is precisely the patient whose cardiovascular risk profile deserves the same rigour applied to her male counterpart with the same history.

The existing urate-lowering conversation

The study does not directly test whether urate-lowering therapy (allopurinol, febuxostat) reduces the cardiovascular risk associated with frequent flares. That is a fair limitation. But the logic is reasonable: if the cardiovascular risk is driven by repeated inflammasome activation from urate crystal deposition, reducing serum urate to target — and thereby reducing flare frequency — should reduce the systemic inflammatory load over time.

This is consistent with existing guidance from the RACGP and Rheumatology societies, which already recommend urate-lowering therapy for patients with two or more flares per year (on the basis of joint outcomes and tophi prevention). The cardiovascular data provide an additional rationale for not delaying that therapy when the frequency threshold has been reached — and for treating the serum urate to target rather than just below the symptomatic threshold.

My two cents

Gout sits in an awkward clinical space. It is painful enough to drive a patient to their GP during a flare, but once the flare resolves — often within days — both the patient and, historically, the treating doctor have tended to shelve the conversation until the next attack. The lifestyle advice is given, the colchicine script is issued, and the long-term urate management conversation does not always happen.

This study changes the frame on what “managing gout well” means. It is not just about preventing joint damage and tophus formation. It is about reducing a systemic inflammatory burden that accumulates with each flare and translates into measurable cardiovascular risk over years.

For a patient in their late 40s or 50s already navigating perimenopause, changing body composition, and early hypertension, the addition of frequent gout flares to the clinical picture is not a minor comorbidity — it is a cardiovascular risk modifier that deserves the same attention as her lipid panel and blood pressure readings.

The practical ask is straightforward. If you have had three or more gout attacks in the last year, that number belongs in a proper cardiovascular risk conversation with your GP — not just as background medical history, but as an active consideration in the risk stratification. That conversation includes: Are we treating your urate to target? Are your blood pressure, lipids, and blood sugar adequately managed? And is there anything in the current clinical picture that warrants closer monitoring than an annual check-in?

These are answerable questions. The study gives GPs a clearer reason to ask them.

Verdict: yes — strong multinational data, clinically actionable threshold, directly relevant to the post-menopausal gout patient who is underrecognised in this risk conversation.

Sources cited

Frequent gout flares flag heart danger. Medical Republic, 23 July 2026. https://www.medicalrepublic.com.au/frequent-gout-flares-flag-heart-danger/127570
Rheumatology — Oxford University Press (journal of original study). https://academic.oup.com/rheumatology